Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.880 UNCHANGED
Streaming Delayed Price Updated: 11:31 AM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma 2024 Financial Calendar
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Regulatory Hurdle For Innate Pharma's Blood Cancer Studies ↗
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201... 
Via Benzinga
News headline image
Innate Pharma Provides Update on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports First Half 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
From Innate Pharma SA
Via Business Wire
News headline image
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
From Innate Pharma SA
Via Business Wire
News headline image
Why Shares of Innate Pharma Jumped Thursday ↗
The company's collaboration agreement with Sanofi could soon pay off. 
Via The Motley Fool
News headline image
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
News headline image
Outcome of Innate Pharma’s 2023 Annual General Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Number of shares and voting rights of Innate Pharma as of May 1, 2023
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
News headline image
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>